We are live on ! Find out more
PPH icon

VanEck Pharmaceutical ETF
PPH

50 hedge funds and large institutions have $105M invested in VanEck Pharmaceutical ETF in 2017 Q1 according to their latest regulatory filings, with 11 funds opening new positions, 12 increasing their positions, 14 reducing their positions, and 11 closing their positions.

New
Increased
Maintained
Reduced
Closed

7% more capital invested

Capital invested by funds: $98.3M → $105M (+$6.57M)

0.61% more ownership

Funds ownership: 37.51% → 38.11% (+0.61%)

0% more first-time investments, than exits

New positions opened: 11 | Existing positions closed: 11

2% less funds holding

Funds holding: 51 → 50 (-1)

14% less repeat investments, than reductions

Existing positions increased: 12 | Existing positions reduced: 14

Holders
50
Holders Change
-1
Holders Change %
-1.96%
% of All Funds
1.24%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
11
Increased
12
Reduced
14
Closed
11
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Citigroup
Citigroup
New York
+$10.9M
2
Goldman Sachs
Goldman Sachs
New York
+$10.8M
3
CCT
Country Club Trust
Missouri
+$677K
4
WI
Wintrust Investments
Illinois
+$317K
5
RJFSA
Raymond James Financial Services Advisors
Florida
+$307K

Top Sellers

Rank Fund Capital Flow
1
JP Morgan Chase
JP Morgan Chase
New York
-$13.6M
2
Bank of America
Bank of America
North Carolina
-$2M
3
CC
Colrain Capital
Massachusetts
-$1.25M
4
Royal Bank of Canada
Royal Bank of Canada
Ontario, Canada
-$959K
5
Creative Planning
Creative Planning
Kansas
-$938K
Name Holding Trade Value Shares
Change 		Change in
Stake
KFC
26
Klingenstein Fields & Co
New York
$210K +$206K +3,800 New
FDCDDQ
27
Federation des caisses Desjardins du Quebec
Quebec, Canada
$187K +$184K +3,400 New
Bank of Montreal
28
Bank of Montreal
Ontario, Canada
$163K – – –
Creative Planning
29
Creative Planning
Kansas
$130K -$938K -17,290 -88%
JP Morgan Chase
30
JP Morgan Chase
New York
$124K -$13.6M -250,057 -99%
TCM
31
Tradewinds Capital Management
Washington
$66K – – –
MIM
32
Macroview Investment Management
Maryland
$64K -$179K -3,302 -74%
MA
33
MUFG Americas
New York
$64K -$2.77K -51 -4%
HCM
34
Highlander Capital Management
New Jersey
$60K – – –
GT
35
Glenmede Trust
Pennsylvania
$55K – – –
ASN
36
Advisory Services Network
Georgia
$48K +$47K +866 New
EDRH
37
Edmond de Rothschild Holding
Switzerland
$22K – – –
WP
38
WealthPLAN Partners
Nebraska
$21.8K +$21.7K +400 New
CPA
39
Clear Perspective Advisors
Illinois
$17K – – –
TRCT
40
Tower Research Capital (TRC)
New York
$16K +$7.11K +131 +78%
Simplex Trading
41
Simplex Trading
Illinois
$14K +$14.5K +268 New
NSIM
42
North Star Investment Management
Illinois
$12K +$1.9K +35 +20%
IA
43
IFP Advisors
Florida
$8K – – –
WA
44
WFG Advisors
Texas
$6K – – –
WEC
45
Winslow Evans & Crocker
Massachusetts
$5.51K – – –
Carson Wealth (CWM LLC)
46
Carson Wealth (CWM LLC)
Nebraska
$5K – – –
FANJ
47
Financial Architects (New Jersey)
New Jersey
$4K +$3.74K +69 New
AG
48
Advisor Group
Arizona
$2K – – –
BFEC
49
Benjamin F. Edwards & Company
Missouri
$1K +$1.08K +20 New
ECM
50
Endurant Capital Management
California
– -$819K -15,600 Closed
1
2
3

PPH Hedge Fund Activity: Q1 2017 in Review

50 of the 4,017 institutional investors tracked by Wall St. Rank reported a position in VanEck Pharmaceutical ETF (PPH) for Q1 2017, worth a combined $105M — up 6.7% from $98.3M a quarter earlier.

Fund positioning in PPH was balanced in Q1 2017: 11 funds opened new positions, 11 closed out, 12 added to existing stakes and 14 trimmed.

The largest buyer was Citigroup, adding an estimated $10.9M. The largest seller was JP Morgan Chase, cutting an estimated $13.6M.

  • 50 institutional investors held VanEck Pharmaceutical ETF (PPH) as of Q1 2017, down from 51 in Q4 2016.
  • Funds reported $105M of VanEck Pharmaceutical ETF stock for Q1 2017, up 6.7% quarter-over-quarter.
  • 11 funds opened new VanEck Pharmaceutical ETF positions in Q1 2017 and 11 closed out, a net change of 0 holders.
  • The largest VanEck Pharmaceutical ETF buyer in Q1 2017 was Citigroup, an estimated $10.9M added.
  • The largest VanEck Pharmaceutical ETF seller in Q1 2017 was JP Morgan Chase, an estimated $13.6M sold.

Based on aggregated 13F filings for Q1 2017.